| | | | | | | | | | |
|
|
|
|
| Dockets Entered
On June 14, 2004
Table of Contents
|
|
|
|
|
|
|
|
|
|
|
| Docket #
|
| Title
|
|
|
|
|
|
|
| 2000D-1392
|
| Guidance for Industry on Botanical Drug Products
|
|
|
|
|
| 2000N-1571
|
| Enrofloxacin for Poultry: Opportunity for Hearing
|
|
|
|
|
| 2001P-0075
|
| Switch Status of Emergency Contraceptives from Rx to OTC
|
|
|
|
|
| 2002D-0509
|
| Intl Conference on Harmonisation/M4 Common Technical Documen
|
|
|
|
|
| 2003P-0029
|
| Remove metered-dose inhalers (MDI) containing moiety albuter
|
|
|
|
|
| 2004N-0018
|
| Human Subject Protection; Foreign Clinical Studies Not Conducted Under an Investigational New Drug Application
|
|
|
|
|
| 2004P-0127
|
| ANADA suitability for ANTIROBE (clindamycin hydrochloride) capsules for dogs and cats (NADA 120-161)
|
|
|
|
|
| 2004P-0263
|
| To declare that the drug Cefixine chewable tablets, 100 mg, 150 mg, and 200 mg are suitable for an abbreviated new drug application ( ANDA)
|
|
|
|
|
| 2000D-1392
|
| Guidance for Industry on Botanical Drug Products
|
|
|
|
|
| GDL
2
|
| Guideline
|
| Vol #:
|
| 1
|
|
|
|
|
| NAD
2
|
| FDA
|
| Vol #:
|
| 1
|
|
|
|
|
| 2000N-1571
|
| Enrofloxacin for Poultry: Opportunity for Hearing
|
|
|
|
|
| EXB 105
|
| Center for Veterinary Medicine
|
| Vol #:
|
| 410
|
|
|
|
|
| EXB 106
|
| Center for Veterinary Medicine
|
| Vol #:
|
| 410
|
|
|
|
|
| EXB 107
|
| Center for Veterinary Medicine
|
| Vol #:
|
| 410
|
|
|
|
|
| EXB 108
|
| Center for Veterinary Medicine
|
| Vol #:
|
| 410
|
|
|
|
|
| EXB 109
|
| Center for Veterinary Medicine
|
| Vol #:
|
| 410
|
|
|
|
|
| EXB 110
|
| Center for Veterinary Medicine
|
| Vol #:
|
| 410
|
|
|
|
|
| 2001P-0075
|
| Switch Status of Emergency Contraceptives from Rx to OTC
|
|
|
|
|
| C 1357
|
| Form Letter
|
| Vol #:
|
| 249
|
|
|
|
|
| C 1358
|
| Form Letter
|
| Vol #:
|
| 250
|
|
|
|
|
| C 1359
|
| Form Letter
|
| Vol #:
|
| 251
|
|
|
|
|
| C 1360
|
| Form Letter
|
| Vol #:
|
| 252
|
|
|
|
|
| C 1361
|
| Form Letter
|
| Vol #:
|
| 253
|
|
|
|
|
| C 1362
|
| Form Letter
|
| Vol #:
|
| 254
|
|
|
|
|
| C 1363
|
| Form Letter
|
| Vol #:
|
| 255
|
|
|
|
|
| C 1364
|
| Form Letter
|
| Vol #:
|
| 256
|
|
|
|
|
| C 1365
|
| Form Letter
|
| Vol #:
|
| 257
|
|
|
|
|
| C 1366
|
| Form Letter
|
| Vol #:
|
| 258
|
|
|
|
|
| C 1367
|
| Form Letter
|
| Vol #:
|
| 259
|
|
|
|
|
| C 1368
|
| Form Letter
|
| Vol #:
|
| 260
|
|
|
|
|
| C 1369
|
| Form Letter
|
| Vol #:
|
| 261
|
|
|
|
|
| C 1370
|
| Form Letter
|
| Vol #:
|
| 262
|
|
|
|
|
| C 1371
|
| Form Letter
|
| Vol #:
|
| 263
|
|
| | | | | | | | |
|
|
|
|
| FONS
1
|
| HFD-7
|
| Vol #:
|
| 3
|
|
|
|
|
| NPR
1
|
| FDA
|
| Vol #:
|
| 3
|
|
|
|
|
| 2004N-0018
|
| Human Subject Protection; Foreign Clinical Studies Not Conducted Under an Investigational New Drug Application
|
|
|
|
|
| NPR
1
|
| FDA
|
| Vol #:
|
| 1
|
|
|
|
|
| 2004P-0127
|
| ANADA suitability for ANTIROBE (clindamycin hydrochloride) capsules for dogs and cats (NADA 120-161)
|
|
|
|
|
| ACK 2
|
| HFA-305 to Smart Drug Systems Inc.
|
| Vol #:
|
| 1
|
|
|
|
|
| 2004P-0263
|
| To declare that the drug Cefixine chewable tablets, 100 mg, 150 mg, and 200 mg are suitable for an abbreviated new drug application ( ANDA)
|
|
|
|
|
| ACK 1
|
| HFA-305 to Lupin Pharmaceuticals, Inc.
|
| Vol #:
|
| 1
|
|
|
|
|
| CP
1
|
| Lupin Pharmaceuticals, Inc.
|
| Vol #:
|
| 1
|
|
